Prashant Kudva

Experience

• 

  Emendo Biotherapeutics

  Vice President of Business Development | Cutting Edge Novel Nuclease Gene Editing Platform

  Feb 2023 - Present

  EmendoBio develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy.

  • Pioneered strategic alliances and licensing agreements to position EmendoBio's gene editing technologies in global markets.
  • Led cross-functional global initiatives to enhance EmendoBio's business development efforts and strategic acquisitions.
  • Drove the expansion of EmendoBio's intellectual property portfolio through strategic M&A and licensing deals.
• 

  Generian

  Head Of Business Development | Novel Platform Targeting Previously Undruggable Targets

  Jun 2021 - Mar 2023

  Generian discovers and develops small molecules that target previously undruggable targets to improve drug development options.

  • Orchestrated and closed a $180 million transformational collaboration, enhancing Generian's market position and drug discovery capabilities.
  • Spearheaded strategic partnerships and licensing opportunities to advance the company’s innovative drug discovery platform.
  • Enhanced Generian's pipeline through targeted outlicensing and partnerships, focusing on difficult-to-drug protein targets.
• 

  Editas Medicine

  Business Development | Gene Editing in Rare Diseases, Oncology and Ophthalmic Disease

  Mar 2020 - Jun 2021

  Editas Medicine focuses on gene-editing technology to develop transformative genomic medicines for people living with serious diseases.

  • Developed and implemented competitive intelligence strategies to maintain Editas' position in the competitive CRISPR space.
  • Established infrastructure improvements, including CRMs and valuation models, to streamline business development processes.
  • Led strategic collaborations to advance gene-edited cell therapy programs, particularly in ophthalmic and rare diseases.
• 

  AMAG Pharmaceuticals

  Business Development | Hematology, Oncology and Women's Health

  Mar 2019 - Mar 2020

  AMAG Pharmaceuticals develops and delivers innovative medicines with a focus on underserved conditions in hematology, oncology, and women’s health.

  • Led the execution of three transformational business transactions to expand AMAG's portfolio and market reach.
  • Evaluated and pursued potential in-licensing opportunities and complementary product acquisitions.
  • Played a pivotal role during AMAG's acquisition by COVIS Pharma, ensuring strategic alignment and business continuity.
• 

  Kaufman Hall

  Vice President - Healthcare Investment Banking

  Jun 2017 - Feb 2019

  Kaufman Hall provides financial and strategic advisory services, helping healthcare organizations achieve operational success and financial sustainability.

• 

  Stifel Financial Corp.

  Executive Director | Healthcare Investment Banking

  Sep 2011 - Jan 2017

  Stifel Financial Corp. offers wealth management and investment banking services, including mergers and acquisitions, underwriting, and capital raising.

• 

  Standard Chartered Bank

  Associate Director

  Jul 2009 - Aug 2011

  Standard Chartered Bank provides banking and financial services to multinational corporations and institutional clients.

• 

  Lazard

  Senior Analyst

  May 2007 - Jul 2009

  Lazard is a financial advisory and asset management firm specializing in mergers, acquisitions, and capital markets across various sectors.

• 

  Merrill Lynch

  Analyst

  Aug 2006 - Mar 2007

  Merrill Lynch provides wealth management, securities trading and sales, and corporate finance services globally.